Bacteria have many strategies for defending themselves against antibiotics. Some destroy the drug, others pump it out or alter its target. They can also, more simply, prevent it from getting in. A team at the University of Geneva (UNIGE) has discovered how Pseudomonas aeruginosa, a bacterium responsible for infections that are often difficult to treat, very rapidly restricts the entry of imipenem, an antibiotic reserved for the most critical cases. Published in the Proceedings of the National Academy of Sciences, these findings reveal a mechanism of antibiotic resistance and open up new avenues for eventually counteracting it.
Pathogen P. aeruginosa uses protein to limit entry of last-resort antibiotic
This article is not about Iran. It reports on research from the University of Geneva regarding how the bacterium Pseudomonas aeruginosa resists the antibiotic imipenem by restricting its entry into cells. The findings have no direct relevance to Iranian affairs or politics.
👥 Key Players
📰 What Happened
Researchers at the University of Geneva discovered how the bacterium Pseudomonas aeruginosa resists imipenem, a last-resort antibiotic, by using a protein to restrict the drug's entry into bacterial cells. The findings were published in the Proceedings of the National Academy of Sciences and reveal a new mechanism of antibiotic resistance.
- P. aeruginosa uses a protein-based mechanism to block imipenem entry
- Imipenem is reserved for critical infections
- The discovery may lead to new strategies to overcome this resistance
💡 Why It Matters
📚 Background
Antibiotic resistance occurs when bacteria develop mechanisms to survive drugs designed to kill them. This is a critical global health challenge affecting treatment of infections worldwide.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%